Please activate JavaScript!
Please install Adobe Flash Player, click here for download
ePaper created 2017-09-29, 09:24:58 | version 1.38.0
Implant Tribune Italian Edition - Settembre 2017 Table 5: Probing depth and bleeding according to aspect during follow-up. Aspect Variable PD ≤ 4 mm > 4–< 6 mm ≥ 6 mm Total BOP Present Absent Total Ricerca & Clinica 9 Table 6: Quantity (mm) of bone loss on radiograph during follow-up. Quantity < 2 mm 2–4 mm > 4 mm n (%) 20 (76.9) 6 (23.1) 0 (0.0) > ½ of implant length 0 (0.0) M n (%) D n (%) B n (%) L/P n (%) 30 (96.8) 28 (90.3) 28 (90.3) 30 (96.8) Total 26 (100.0) 1 (3.2) 0 (0.0) 0 (0.0) 3 (9.7) 0 (0.0) 3 (9.7) 0 (0.0) 1 (3.2) 31 (100.0) 31 (100.0) 31 (100.0) 31 (100.0) 5 (16.1) 3 (9.7) 5 (16.1) 5 (16.1) 26 (83.9) 28 (90.3) 26 (83.9) 26 (83.9) 31 (100.0) 31 (100.0) 31 (100.0) 31 (100.0) implants showed bone loss of between 2 and 4 mm, while the remaining implants presen- ted with less than 2 mm (Table 6). Analyzing all of the parameters established a success rate of 74% (20 implants), while 26% of the implants (six implants) were classifi ed as ha- ving impaired survival (Fig. 1). The implants that had impaired survival showed different characteristics regarding location, size and PD. Regarding the height of these implants, three were longer than 12 mm, two were 10–12 mm in height and one less than 10 mm in height. Concerning the diameter, four of these im- plants were narrow and two were regular. PD = probing depth; BOP = bleeding on probing; M = mesial; D = distal; B = buccal; L/P = lingual/palatal. f> pagina 10 f< pagina 8 For the assessment of radiographic bone loss, a periapical radiograph using the bisecting angle technique was performed at the time of patient recall. The radiographs were digitalized and analyzed using the Image Tool software (Trophy-Radiologie, Vincennes, France) to verify and determine the resulting linear distance between the implant shoulder and bone crest. The average values for the M and D aspects were used as a single measurement for each implant. From this analysis, the implants were divi- ded into the following categories: bone loss of less than 2 mm; bone loss of between 2 and 4 mm; bone loss of more than 4 mm, but less than half of the implant body; and bone loss greater than half of the length of the implant. According to these criteria, the im- plants were classifi ed as successful, having satisfactory survival, having impaired survi- val or failed. Biological and prosthetic com- plications, such as periimplant mucositis, periimplantitis, abscesses or fi stulas, or any mechanical and prosthetic complications, such as fracture of the implant and/or of any prosthetic component, were also evaluated. Patients with BOP or positive suppuration, a PD of greater than 5 mm and radiographic bone loss were diagnosed as having periim- plantitis10. Resufts The study included 35 implants placed in 19 patients, six men and 13 women, with the following age distribution: two patients aged between 30 and 39, six patients between 40 and 49, seven patients between 50 and 59, three patients between 60 and 69, and one patient between 70 and 79. The prevalence of systemic disease and a smoking habit was assessed by interview and the results are pre- sented in Table 1. The implants were classifi ed according to the placement area: mandible and maxilla and anterior and posterior (Table 2). Three patients were rehabilitated with full- arch fi xed prostheses supported by osseoin- tegrated implants, 20 received single pros- theses and two received an overdenture. Concer- ning the implant diame- ter, 80% of the implants were classifi ed as narrow and 20% as regular (Table 3). Regarding the implant height, 14.28% of the im- plants were classifi ed as short, 54.28% as regular and 31.46% as long (Table 3). A higher frequency of implants of 11 mm in height and less than 4 mm in diameter was observed. Regarding the presence of clinical signs associated with the implants, such as pain, exudate and mobili- ty, 18 patients (who recei- ved 34 implants) reported no pain. The presence of pain in function occurred in only one implant and the presence of exudate in two (Table 4). In general, PDs of less than 4 mm were obser- ved in most cases. Only one implant showed a PD of 5 mm at the M aspect, while a PD of 6 mm and BP were observed at one implant at the L/P aspect and at three implants at the D and B aspects. BOP was present at fi ve implants at the M, B and L/P aspects, and at three implants at the D aspect (Table 5). Four implants could not be evaluated owing to the presence of a protocol-type prosthe- sis. Twenty-six of the 35 implants were evaluated in periapical radiographs by measuring the linear distance between the im- plant shoulder and bone crest. Only 17.1% of the implants Uno scudo biologico, sempre intatto Concetto On1™ On1 è la prima soluzione che preserva l’attacco del tessuto molle mantenendo la completa flessibilità chirurgica e protesica. L’On1 Base sposta la piattaforma protesica al livello del tessuto molle, semplificando radicalmente tutte le procedure protesiche. Sperimenta il meglio con il concetto On1. Visita nobelbiocare.com/on1 GMT 50890 IT 1703 Stampato in EU © Nobel Biocare Services AG, 2017. Tutti i diritti riservati. Nobel Biocare, il logo Nobel Biocare e tutti gli altri marchi di fabbrica sono, salvo diversa dichiarazione o evidenza dal contesto in un caso specifico, marchi di fabbrica di Nobel Biocare. Fare riferimento al sito nobelbiocare.com/trademarks per maggiori informazioni. Le immagini dei prodotti non sono necessariamente in scala. Esclusione di responsabilità: alcuni prodotti potrebbero non avere l’approvazione o l’autorizzazione alla vendita da parte degli enti normativi in tutti i mercati. Rivolgersi all’ufficio vendite locale Nobel Biocare per informazioni sulla gamma dei prodotti esistenti e la loro disponibilità. Per uso solo su prescrizione medica. Fare riferimento alle istruzioni per l’uso relativamente a informazioni sulla prescrizione incluse indicazioni, controindicazioni, avvertenze e precauzioni.